282 related articles for article (PubMed ID: 19018005)
1. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
[TBL] [Abstract][Full Text] [Related]
2. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.
Beum PV; Kennedy AD; Williams ME; Lindorfer MA; Taylor RP
J Immunol; 2006 Feb; 176(4):2600-9. PubMed ID: 16456022
[TBL] [Abstract][Full Text] [Related]
3. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
[TBL] [Abstract][Full Text] [Related]
4. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
5. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
6. Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.
Taylor RP; Lindorfer MA
Blood; 2015 Jan; 125(5):762-6. PubMed ID: 25498911
[TBL] [Abstract][Full Text] [Related]
7. Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous Controls.
Taylor RP; Lindorfer MA
Curr Protoc; 2023 Oct; 3(10):e897. PubMed ID: 37830752
[TBL] [Abstract][Full Text] [Related]
8. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.
Boross P; Jansen JH; Pastula A; van der Poel CE; Leusen JH
Immunol Lett; 2012 Mar; 143(1):44-52. PubMed ID: 22285696
[TBL] [Abstract][Full Text] [Related]
9. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies.
Taylor RP; Lindorfer MA
Mol Pharmacol; 2014 Nov; 86(5):485-91. PubMed ID: 24944188
[TBL] [Abstract][Full Text] [Related]
10. Antigenic modulation and rituximab resistance.
Taylor RP; Lindorfer MA
Semin Hematol; 2010 Apr; 47(2):124-32. PubMed ID: 20350659
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.
Li Y; Williams ME; Cousar JB; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2007 Sep; 179(6):4263-71. PubMed ID: 17785867
[TBL] [Abstract][Full Text] [Related]
12. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Beers SA; French RR; Chan HT; Lim SH; Jarrett TC; Vidal RM; Wijayaweera SS; Dixon SV; Kim H; Cox KL; Kerr JP; Johnston DA; Johnson PW; Verbeek JS; Glennie MJ; Cragg MS
Blood; 2010 Jun; 115(25):5191-201. PubMed ID: 20223920
[TBL] [Abstract][Full Text] [Related]
13. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
[TBL] [Abstract][Full Text] [Related]
14. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
Kennedy AD; Solga MD; Schuman TA; Chi AW; Lindorfer MA; Sutherland WM; Foley PL; Taylor RP
Blood; 2003 Feb; 101(3):1071-9. PubMed ID: 12393727
[TBL] [Abstract][Full Text] [Related]
15. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
16. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
17. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies.
Pedersen AE; Jungersen MB; Pedersen CD
Immunology; 2011 Jun; 133(2):239-45. PubMed ID: 21426340
[TBL] [Abstract][Full Text] [Related]
18. Induction of interleukin-6 production by rituximab in human B cells.
Jones JD; Hamilton BJ; Skopelja S; Rigby WF
Arthritis Rheumatol; 2014 Nov; 66(11):2938-46. PubMed ID: 25080282
[TBL] [Abstract][Full Text] [Related]
19. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
20. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.
Taylor RP; Lindorfer MA
Nat Clin Pract Rheumatol; 2007 Feb; 3(2):86-95. PubMed ID: 17299446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
